Author: MIRA Pharmaceuticals

Posted Date:

June 4, 2026

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

MIRA Pharmaceuticals

June 4, 2026
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

MIRA Pharmaceuticals

May 13, 2026
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

MIRA Pharmaceuticals

March 23, 2026